Cargando…
Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women
OBJECTIVE: To describe the clinical presentation and laboratory diagnosis of pregnant women with respiratory syncytial virus (RSV) infection. METHODS: Pregnant women in their second and third trimester were enrolled during the course of routine prenatal care visits when they were asymptomatic within...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126758/ https://www.ncbi.nlm.nih.gov/pubmed/31085002 http://dx.doi.org/10.1016/j.vaccine.2019.04.098 |
_version_ | 1783516214768697344 |
---|---|
author | Hause, Anne M. Avadhanula, Vasanthi Maccato, Maurizio L. Pinell, Phillip M. Bond, Nanette Santarcangelo, Patricia Ferlic-Stark, Laura Ye, Xunyan Iwuchukwu, Obinna Maurer, Lauren Aideyan, Letisha Dao, Kelly McBride, Trevor Piedra, Pedro A. Munoz, Flor M. |
author_facet | Hause, Anne M. Avadhanula, Vasanthi Maccato, Maurizio L. Pinell, Phillip M. Bond, Nanette Santarcangelo, Patricia Ferlic-Stark, Laura Ye, Xunyan Iwuchukwu, Obinna Maurer, Lauren Aideyan, Letisha Dao, Kelly McBride, Trevor Piedra, Pedro A. Munoz, Flor M. |
author_sort | Hause, Anne M. |
collection | PubMed |
description | OBJECTIVE: To describe the clinical presentation and laboratory diagnosis of pregnant women with respiratory syncytial virus (RSV) infection. METHODS: Pregnant women in their second and third trimester were enrolled during the course of routine prenatal care visits when they were asymptomatic within the preceding two weeks (healthy controls) or when they reported symptoms of acute respiratory illness (ARI) of ≤7 days of duration (cases). Clinical outcomes were assessed at enrollment and two weeks after. Re-enrollment was allowed. Nasal-pharyngeal secretions were evaluated for respiratory pathogens by real-time reverse transcription polymerase chain reaction (PCR). Sera were tested for RSV-specific antibody responses by Western Blot, microneutralization assay, and palivizumab competitive antibody assay. RESULTS: During the 2015–2016 respiratory virus season, 7 of 65 (11%) pregnant women with ARI at their initial enrollment and 8 of 77 (10%) pregnant women with ARI during the study period (initial or re-enrollment) had PCR-confirmed RSV infection. Four (50%) PCR-confirmed RSV ARI cases reported symptoms of a lower respiratory tract illness (LRTI), one was hospitalized. Combining PCR and serology data, the RSV attack rate at initial enrollment was 12% (8 of 65), and 13% (10 of 77) based on ARI episodes. Among healthy controls, 28 of 88 (32%) had a Western Blot profile suggestive of a recent RSV infection either in the prior and/or current season. CONCLUSION: RSV had an attack rate of 10–13% among ambulatory pregnant women receiving routine prenatal care during the respiratory virus season. The serology results of healthy controls suggest a potentially higher attack rate. Future studies should be aware of the combined diagnostic strength of PCR and serology to identify RSV infection. As maternal RSV vaccine candidates are evaluated to protect young infants, additional priority should be placed on outcomes of pregnant women. |
format | Online Article Text |
id | pubmed-7126758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71267582020-04-08 Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women Hause, Anne M. Avadhanula, Vasanthi Maccato, Maurizio L. Pinell, Phillip M. Bond, Nanette Santarcangelo, Patricia Ferlic-Stark, Laura Ye, Xunyan Iwuchukwu, Obinna Maurer, Lauren Aideyan, Letisha Dao, Kelly McBride, Trevor Piedra, Pedro A. Munoz, Flor M. Vaccine Article OBJECTIVE: To describe the clinical presentation and laboratory diagnosis of pregnant women with respiratory syncytial virus (RSV) infection. METHODS: Pregnant women in their second and third trimester were enrolled during the course of routine prenatal care visits when they were asymptomatic within the preceding two weeks (healthy controls) or when they reported symptoms of acute respiratory illness (ARI) of ≤7 days of duration (cases). Clinical outcomes were assessed at enrollment and two weeks after. Re-enrollment was allowed. Nasal-pharyngeal secretions were evaluated for respiratory pathogens by real-time reverse transcription polymerase chain reaction (PCR). Sera were tested for RSV-specific antibody responses by Western Blot, microneutralization assay, and palivizumab competitive antibody assay. RESULTS: During the 2015–2016 respiratory virus season, 7 of 65 (11%) pregnant women with ARI at their initial enrollment and 8 of 77 (10%) pregnant women with ARI during the study period (initial or re-enrollment) had PCR-confirmed RSV infection. Four (50%) PCR-confirmed RSV ARI cases reported symptoms of a lower respiratory tract illness (LRTI), one was hospitalized. Combining PCR and serology data, the RSV attack rate at initial enrollment was 12% (8 of 65), and 13% (10 of 77) based on ARI episodes. Among healthy controls, 28 of 88 (32%) had a Western Blot profile suggestive of a recent RSV infection either in the prior and/or current season. CONCLUSION: RSV had an attack rate of 10–13% among ambulatory pregnant women receiving routine prenatal care during the respiratory virus season. The serology results of healthy controls suggest a potentially higher attack rate. Future studies should be aware of the combined diagnostic strength of PCR and serology to identify RSV infection. As maternal RSV vaccine candidates are evaluated to protect young infants, additional priority should be placed on outcomes of pregnant women. Elsevier Ltd. 2019-06-06 2019-05-10 /pmc/articles/PMC7126758/ /pubmed/31085002 http://dx.doi.org/10.1016/j.vaccine.2019.04.098 Text en © 2019 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Hause, Anne M. Avadhanula, Vasanthi Maccato, Maurizio L. Pinell, Phillip M. Bond, Nanette Santarcangelo, Patricia Ferlic-Stark, Laura Ye, Xunyan Iwuchukwu, Obinna Maurer, Lauren Aideyan, Letisha Dao, Kelly McBride, Trevor Piedra, Pedro A. Munoz, Flor M. Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women |
title | Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women |
title_full | Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women |
title_fullStr | Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women |
title_full_unstemmed | Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women |
title_short | Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women |
title_sort | clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126758/ https://www.ncbi.nlm.nih.gov/pubmed/31085002 http://dx.doi.org/10.1016/j.vaccine.2019.04.098 |
work_keys_str_mv | AT hauseannem clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT avadhanulavasanthi clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT maccatomauriziol clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT pinellphillipm clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT bondnanette clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT santarcangelopatricia clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT ferlicstarklaura clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT yexunyan clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT iwuchukwuobinna clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT maurerlauren clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT aideyanletisha clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT daokelly clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT mcbridetrevor clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT piedrapedroa clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen AT munozflorm clinicalcharacteristicsandoutcomesofrespiratorysyncytialvirusinfectioninpregnantwomen |